Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SGA400
- Development stage
- Preclinical
- Lead developer
- BMG Pharma
- Administration
- Intraarticular
01
Overview
SGA400 is a preclinical-stage intra-articular injection developed by BMG Pharma for the treatment of osteoarthritis. It is classified as a Class 3 medical device and is built upon the company's proprietary Hyaluromimetic® technology platform, which incorporates sodium hyaluronate lipoate and formate. The product is designed to improve cartilage lubrication and alleviate joint pain by mimicking the viscoelastic properties of natural synovial fluid. As of the latest pipeline information, SGA400 is in the preclinical stage of development.
- Other names
- SGA400 Intra Articular InjectionSGA-400 Intra Articular InjectionSGA 400 Intra Articular Injection
Beyond the preview
Go deeper on SGA400.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SGA400.